Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1950 4
1951 2
1952 1
1953 3
1954 3
1955 3
1956 4
1957 3
1958 1
1959 5
1960 1
1961 2
1962 1
1963 2
1964 1
1966 3
1967 3
1968 3
1969 4
1970 2
1971 1
1972 2
1973 5
1974 5
1975 5
1976 7
1977 14
1978 12
1979 9
1980 9
1981 8
1982 6
1983 8
1984 14
1985 11
1986 6
1987 5
1988 10
1989 9
1990 8
1991 20
1992 20
1993 14
1994 15
1995 18
1996 19
1997 24
1998 24
1999 17
2000 20
2001 26
2002 26
2003 28
2004 40
2005 22
2006 35
2007 30
2008 48
2009 62
2010 45
2011 60
2012 63
2013 72
2014 72
2015 77
2016 73
2017 73
2018 68
2019 98
2020 112
2021 122
2022 128
2023 123
2024 113
2025 119
2026 63

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,929 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. Among authors: berg s. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Apolo AB, et al. Among authors: berg s. N Engl J Med. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15. N Engl J Med. 2025. PMID: 39282902 Free PMC article. Clinical Trial.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: berg s. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
[S.H. Berg responds].
Berg SH. Berg SH. Tidsskr Nor Laegeforen. 2023 Sep 4;143(12). doi: 10.4045/tidsskr.23.0537. Print 2023 Sep 5. Tidsskr Nor Laegeforen. 2023. PMID: 37668120 Free article. Norwegian. No abstract available.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Ferrante M, et al. Among authors: berg s. Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. Lancet. 2022. PMID: 35644155 Clinical Trial.
Author Reply.
van den Berg S, de Visser SJ, Timmers L, Hollak CEM. van den Berg S, et al. Value Health. 2022 Jan;25(1):158-159. doi: 10.1016/j.jval.2021.08.005. Epub 2021 Sep 21. Value Health. 2022. PMID: 35031095 Free article. No abstract available.
Approach to the Patient With Raised Thyroid Hormones and Nonsuppressed TSH.
Moran C, Schoenmakers N, Halsall D, Oddy S, Lyons G, van den Berg S, Gurnell M, Chatterjee K. Moran C, et al. Among authors: van den berg s. J Clin Endocrinol Metab. 2024 Mar 15;109(4):1094-1108. doi: 10.1210/clinem/dgad681. J Clin Endocrinol Metab. 2024. PMID: 37988295 Free PMC article.
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN, Yi JS, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Mhlanga JC, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Chi SN, et al. Among authors: berg sl. J Natl Cancer Inst. 2023 Nov 8;115(11):1355-1363. doi: 10.1093/jnci/djad085. J Natl Cancer Inst. 2023. PMID: 37228094 Free PMC article.
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, Siffledeen J, Lukin DJ, Wright J, Watanabe K, Ford S, Remple VP, Lacerda AP, Dubcenco E, Garrison A, Zhou Q, Berg S, Anyanwu SI, Schreiber S. Peyrin-Biroulet L, et al. Among authors: berg s. Clin Gastroenterol Hepatol. 2024 Oct;22(10):2096-2106. doi: 10.1016/j.cgh.2024.02.026. Epub 2024 Mar 15. Clin Gastroenterol Hepatol. 2024. PMID: 38492904 Free article. Clinical Trial.
1,929 results